Terms of Reference

The SAGE Working Group (WG) will facilitate a yearly SAGE independent review of the implementation of the Decade of Vaccines’ Global Vaccine Action Plan (GVAP) and assessment of progress.

Specifically, the WG will:

1. review the quality of the data on the GVAP indicators and make recommendations on changes to the formulation of the indicators, operational definitions and/or the processes for data collection;
2. independently evaluate and document progress towards each of the 6 GVAP Strategic Objectives and towards the achievement of the Decade of Vaccines Goals (2011-2020), using the GVAP Monitoring & Evaluation / Accountability Framework;
3. identify successes, challenges and areas where additional efforts or corrective actions by countries, regions, partners, donor agencies or other parties, are needed;
4. identify and document best practices;
5. prepare the GVAP implementation annual report to be presented to the SAGE, and thereafter, with SAGE inputs, be submitted for discussion to the WHO January EB meeting, to the WHA and the independent Expert Review Group (iERG) for the UN Secretary General’s Global Strategy for Women’s and Children’s Health .

In its review the WG should take a broad perspective, encompassing the general environment, including the health system context.

Composition

SAGE Members

• Noni MacDonald (Chair of the Working Group as of June 2017 to replace Narendra Arora), Professor Paediatrics, Dalhousie University, IWK Health Centre, Canada
• Ezzeddine Mohsni (joining SAGE in January 2019), Senior Technical Adviser in GHD/EMPHNET (Global Health Development / Eastern Mediterranean Public Health Network)

Experts

• Jon Kim Andrus, Adjunct Professor and Director, Division of Vaccines and Immunization, Center for Global Health, University of Colorado, USA
• Yagob Al-Mazrou, Secretary General - Health Services Council of the Kingdom of Saudi Arabia, Saudi Arabia
• Narendra Arora, Executive director, International Clinical Epidemiology Network, India
• Susan Elden, Health Adviser, Department for International Development, London, UK
• Marie-Yvette Madrid, Independent Consultant, Geneva, Switzerland
• Rebecca Martin, Director of the Center for Global Health, US CDC, USA
• Amani Mahmoud Mustafa, Project Manager, Sudan Public Health Training Initiative, Carter Center, Sudan
• Helen Rees, Executive Director, Wits Reproductive Health and HIV Institute, Personal Professor, Ob/Gyn Codirector, African Leadership in Vaccinology Excellence, University of Witwatersrand, South Africa
• David Salisbury, Associate Fellow, Centre on Global Health Security, Chatham House, London, UK
• Qinjian Zhao, Associate Dean, School of Public Health, Xiamen University, Xiamen, Fujian, China

Secretariat members

• DoV Secretariat coordinator: WHO, Christoph Steffen
• Bill & Melinda Gates Foundation: Magdalena Robert
• GAVI Alliance: Hope Johnson
• National Institute of Allergy and Infectious Diseases: Lee Hall
• UNICEF: Robin Nandy
• WHO: Joachim Hombach

Past Working Group Members

• Shawn Gilchrist, President S Gilchrist Consulting Services Inc., Canada (resigned from the Working Group May 2014 for personal reasons and replaced by Yvette Madrid)
• Fuqiang Cui, Epidemiology Professor, Deputy Director National Immunization Program, China CDC, China. Member of the Working Group from March 2013 to March 2016.
• Elizabeth Ferdinand, Associate Lecturer, University of the West Indies – Cave Hill, Barbados (affiliation as of January 2015 and previously Senior Medical Officer of Health and EPI Manager, Barbados). Member of the Working Group from March 2013 to March 2016.
• Alan Hinman, Senior Public Health Scientist - Task Force for Global Health, USA. Member of the Working Group from March 2013 to March 2016.
• Stephen Inglis, Director National Institute Biological Standards & Control, Health Protection Agency, UK. Member of the Working Group from March 2013 to March 2016.
• Rozina Mistry, Lecturer and Course Director, Aga Kahn University, Pakistan. Member of the Working Group from March 2013 to March 2016.
• Budihardja Singgih, Technical Director Program Australia Indonesia Partnership for Health Systems Strengthening, Jakarta, Indonesia (resigned in July 2018 for personal reasons)

Declarations of Interest

All members completed a declaration of interests. Five members reported relevant interests summarized below.

Current members

Marie-Yvette Madrid

• Served as employee of PATH on vaccine related issues until 2014. This interest was assessed as personal, non-specific and financially significant*.
• Provided teaching for IS Global on vaccine related issues in May 2015. This interest was assessed as personal, non-specific and financially insignificant*.
• Serves as consultant for WHO on vaccine related issues. This interest was assessed as personal, non-specific and financially insignificant*.

David Salisbury

• Serves as consultant for GSK, Merck, Takeda, Astra Zeneca, Johnsen on vaccine related issues. This interest was assessed as personal, non-specific and financially significant*.

Past members

Shawn Gilchrist (resigned May 2014 for personal reasons)

• As an exclusive source of income, he provides consultancy services to Sanofi, GlaxoSmithKline, IFPMA, Vaccines Europe and PhRMA Japan. This interest was assessed as personal, non-specific and financially significant*.

Alan Hinman

• His institution receives a policy grant from Novartis to establish a rabies vaccine and immunoglobulin stockpile which is used to cover 10% of his income. This interest was assessed as non-personal, non-specific and financially significant*.

Stephen Inglis

• Serves as director of the National Institute for Biological Standards and Control (NIBSC), a centre of the Health Protection Agency, a not-for-profit, public body whose purpose is to safeguard and enhance public health through the standardisation and control of biologicals used in medicine, engaging with various commercial organizations. This interest was assessed as non-personal, non-specific and financially significant*.

* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single vaccine manufacturer or other vaccine-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in excess of 1,000 USD would also constitute a “significant shareholding”.